Myriad brings cancer tests to India; OPKO finalizes $1.47B Bio-Reference Laboratories deal;

> Myriad Genetics ($MYGN) is partnering with India's Positive Bioscience to bring its molecular genomic tests for cancer to the country. Story

> Miami, FL-based OPKO Health sealed its $1.47 billion deal for sequencing company Bio-Reference Laboratories. Statement

> RainDance Technologies shimmied away from an IPO, deciding to withdraw plans to go public due to "market conditions." More

> Vermillion ($VRML) snagged CareFirst Blue Cross/Blue Shield coverage for its OVA1 ovarian cancer test. Statement

And Finally… Cambridge, MA-based Exosome Diagnostics is charging ahead with development of its liquid biopsy tests for lung cancer, planning to launch the products later this year. Story